Genoptix, Inc. is an American company that provides clinical oncology laboratory services. It specializes in hematology and solid tumors.

According to a press release, the Complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material misrepresentations to the market which had the effect of artificially inflating the market price. The class period is from July 31, 2009 through June 15, 2010.

On April 6, 2011, Judge John A. Houston granted the motion to consolidate several actions under Master File in 10cv2502, approved the City of Ann Arbor Employees’ Retirement System as lead Plaintiff, and approved lead Plaintiff’s selection of Robbins Geller Rudman & Dowd LLP as lead Counsel. On May 31, 2011, the lead Plaintiff filed a Consolidated Class Action Complaint. The Defendants responded by filing a motion to dismiss the Complaint.

On July 11, 2012, the Court issued an Order granting the Defendant's motion to dismiss without prejudice. Plaintiffs were granted leave to amend their Complaint within 30 days of the order. On August 10, 2012, the Plaintiffs filed their amended Complaint.

On March 22, 2013, the Court issued an Order granting in part and denying in part Defendants' Motion to Dismiss.

On February 10, 2014, the parties entered into a Stipulation of Settlement. The Court granted preliminary approval of the Settlement on March 17. On June 20, the Court granted final approval of the Settlement, including an award of Attorneys’ Fees and Expenses, and June 23, the Court entered Final Judgment.